D2M Biotherapeutics, Inc.
NATICK, Massachusetts, United States
Dong Zhang's academic journey began in China, culminating a Bachelor's degree from Jilin University in 1988 and a Ph.D. from the esteemed Chinese Academy of Sciences in 1994. He underwent transformative postdoctoral training in Dr. Judy Lieberman's Harvard Medical School laboratory, engaging in nine years of cutting-edge research in cellular immunology.
In 2005, Dr. Zhang joined the EMD Serono Research and Development Center, entering the nascent field of tumor immunotherapy. Over 15 years, he emerged as a trailblazer, closely tracking the evolution of immune checkpoint inhibitors and assuming a leadership role. Leading ten Discovery Project teams, he delivered four clinical drug candidates, including the FDA-approved Bavencio (ant-PD-L1) and Phase III asset M7824. Both achieved global recognition, ranking among the world's top assets for single asset licensing deals, with tag prices of 2.85 billion and 4.2 billion.
Before co-founding D2M in 2020, Dr. Zhang served as Director of ImmunoOncology, spearheading the In Vitro Pharmacology function. As Chief Scientific Officer at D2M, he leads the discovery and development of innovative immunotherapies for cancer and autoimmune diseases. In the past five years, Dr. Zhang's leadership propelled the R&D team forward, notably advancing DM919 into the clinical stage. His illustrious career continues to shape cancer immunotherapy, showcasing a commitment to innovation and excellence in drug development.
Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): No financial relationships with ineligible companies to disclose
